



March 8, 2016

## **Galectin Therapeutics to Hold Business Update Conference Call on March 15**

NORCROSS, Ga., March 08, 2016 (GLOBE NEWSWIRE) -- **Galectin Therapeutics, Inc.** (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that in conjunction with the filing of its annual report on form 10-K, it will hold a business update conference call on Tuesday, March 15, 2016 at 8:30 a.m. Eastern Time. A question and answer session will be available following management's prepared remarks.

To access the conference call, U.S.-based listeners should dial 844-236-5620 and international listeners should dial 330-863-3454. All listeners should provide the following passcode: 65873987. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website at [www.galectintherapeutics.com](http://www.galectintherapeutics.com).

Following the conclusion of the conference call, a replay will be available through March 20, 2016 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 65873987. The webcast will be available on the Company's website at [www.galectintherapeutics.com](http://www.galectintherapeutics.com) for 90 days.

### **About Galectin Therapeutics**

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at [www.galectintherapeutics.com](http://www.galectintherapeutics.com).

### **Contacts**

Jack Callicutt, Chief Financial Officer

(678) 620-3186

[ir@galectintherapeutics.com](mailto:ir@galectintherapeutics.com)

LHA

Kim Golodetz

(212) 838-3777

[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.